Xin Lang Cai Jing·2026-02-13 04:42Core Viewpoint - The news highlights the administrative penalties imposed on 聚石化学 (Jushi Chemical) and 中泰化学 (Zhongtai Chemical) for engaging in fraudulent activities that inflated their financial statements, leading to potential investor claims for compensation [1][2][5]. Summary by Sections 聚石化学 (Jushi Chemical) - 聚石化学 was found to have inflated its revenue, costs, and profits through fictitious trade activities, including transactions with four companies that did not involve actual goods, resulting in a revenue inflation of approximately 86.55 million yuan and cost inflation of about 88.24 million yuan [1][2]. - The company also engaged in transactions that lacked commercial substance, inflating both revenue and costs by approximately 52.24 million yuan, without affecting profits [1][2]. - In total, for the first half of 2023, 聚石化学 inflated its operating revenue by approximately 156.81 million yuan and operating costs by about 158.47 million yuan, which represented 8.32% and 8.51% of total revenue and costs, respectively [2][5]. - Investors who purchased 聚石化学 stock between August 29, 2023, and November 22, 2025, may initiate claims for compensation due to these fraudulent activities [2][5]. 中泰化学 (Zhongtai Chemical) - 中泰化学 was found to have inflated its 2022 revenue and costs by approximately 4.25 billion yuan each, which accounted for 7.60% and 7.75% of the reported total revenue and costs in its annual report [6]. - The company failed to disclose significant related-party transactions involving non-operating fund occupations in its 2021 and 2022 annual reports, leading to major omissions [3][6]. - Investors who bought 中泰化学 stock between April 10, 2021, and March 21, 2024, are eligible to file claims for compensation due to the identified fraudulent activities [4][6].